Astellas Pharma Inc. (4503.T)
JPY 1521.5
(0.8%)
JPY 1521.5
(0.8%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1034.29 Billion JPY | -5.86% |
| 2022 | 1098.7 Billion JPY | 20.45% |
| 2021 | 912.19 Billion JPY | 5.1% |
| 2020 | 867.89 Billion JPY | 11.49% |
| 2019 | 778.45 Billion JPY | 1.26% |
| 2018 | 768.76 Billion JPY | -2.74% |
| 2017 | 790.38 Billion JPY | 8.5% |
| 2016 | 728.46 Billion JPY | -7.42% |
| 2015 | 786.88 Billion JPY | 8.0% |
| 2014 | 728.61 Billion JPY | 5.0% |
| 2013 | 693.92 Billion JPY | 31.52% |
| 2012 | 527.61 Billion JPY | 1.61% |
| 2011 | 519.23 Billion JPY | -3.63% |
| 2010 | 538.79 Billion JPY | 18.92% |
| 2009 | 453.05 Billion JPY | 11.03% |
| 2008 | 408.02 Billion JPY | -2.23% |
| 2007 | 417.34 Billion JPY | -6.44% |
| 2006 | 446.04 Billion JPY | 7.91% |
| 2005 | 413.34 Billion JPY | 109.83% |
| 2004 | 196.99 Billion JPY | -16.69% |
| 2003 | 236.45 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 285.04 Billion JPY | -13.97% |
| 2024 Q1 | 331.33 Billion JPY | 22.26% |
| 2023 Q1 | 260.98 Billion JPY | -23.27% |
| 2023 Q2 | 320.95 Billion JPY | 22.98% |
| 2023 FY | 1034.29 Billion JPY | -5.86% |
| 2023 Q3 | 327.16 Billion JPY | 1.94% |
| 2023 Q4 | 271 Billion JPY | -17.17% |
| 2022 Q4 | 340.11 Billion JPY | 27.86% |
| 2022 Q2 | 232.3 Billion JPY | -10.75% |
| 2022 FY | 1098.7 Billion JPY | 20.45% |
| 2022 Q1 | 260.29 Billion JPY | 1.2% |
| 2022 Q3 | 266 Billion JPY | 14.51% |
| 2021 Q1 | 228.11 Billion JPY | -16.88% |
| 2021 Q2 | 208.95 Billion JPY | -8.4% |
| 2021 Q4 | 257.2 Billion JPY | 18.02% |
| 2021 FY | 912.19 Billion JPY | 5.1% |
| 2021 Q3 | 217.92 Billion JPY | 4.29% |
| 2020 Q3 | 184.64 Billion JPY | -16.94% |
| 2020 FY | 867.89 Billion JPY | 11.49% |
| 2020 Q1 | 186.47 Billion JPY | -25.82% |
| 2020 Q2 | 222.31 Billion JPY | 19.22% |
| 2020 Q4 | 274.45 Billion JPY | 48.64% |
| 2019 Q3 | 179.06 Billion JPY | 10.4% |
| 2019 FY | 778.45 Billion JPY | 1.26% |
| 2019 Q1 | 185.8 Billion JPY | -7.98% |
| 2019 Q2 | 162.18 Billion JPY | -12.71% |
| 2019 Q4 | 251.39 Billion JPY | 40.4% |
| 2018 Q2 | 181.56 Billion JPY | -6.67% |
| 2018 Q3 | 190.73 Billion JPY | 5.05% |
| 2018 Q4 | 201.91 Billion JPY | 5.86% |
| 2018 FY | 768.76 Billion JPY | -2.74% |
| 2018 Q1 | 194.54 Billion JPY | -7.82% |
| 2017 Q2 | 194.62 Billion JPY | -2.38% |
| 2017 FY | 790.38 Billion JPY | 8.5% |
| 2017 Q4 | 211.04 Billion JPY | 13.87% |
| 2017 Q3 | 185.33 Billion JPY | -4.77% |
| 2017 Q1 | 199.37 Billion JPY | -3.32% |
| 2016 Q2 | 174.64 Billion JPY | 0.97% |
| 2016 Q4 | 206.22 Billion JPY | 18.09% |
| 2016 Q3 | 174.62 Billion JPY | -0.01% |
| 2016 Q1 | 172.97 Billion JPY | -16.75% |
| 2016 FY | 728.46 Billion JPY | -7.42% |
| 2015 Q2 | 194.78 Billion JPY | 1.75% |
| 2015 Q1 | 191.43 Billion JPY | -2.76% |
| 2015 FY | 786.88 Billion JPY | 8.0% |
| 2015 Q4 | 207.78 Billion JPY | 7.72% |
| 2015 Q3 | 192.88 Billion JPY | -0.98% |
| 2014 Q3 | 199.04 Billion JPY | 21.45% |
| 2014 Q2 | 163.89 Billion JPY | -2.92% |
| 2014 FY | 728.61 Billion JPY | 5.0% |
| 2014 Q1 | 168.82 Billion JPY | -27.05% |
| 2014 Q4 | 196.86 Billion JPY | -1.1% |
| 2013 FY | 693.92 Billion JPY | 31.52% |
| 2013 Q4 | 231.43 Billion JPY | 44.86% |
| 2013 Q3 | 159.76 Billion JPY | 5.08% |
| 2013 Q2 | 152.04 Billion JPY | 0.91% |
| 2013 Q1 | 150.68 Billion JPY | -1.61% |
| 2012 Q4 | 153.13 Billion JPY | 12.38% |
| 2012 FY | 527.61 Billion JPY | 1.61% |
| 2012 Q1 | 116.9 Billion JPY | -18.5% |
| 2012 Q2 | 121.3 Billion JPY | 3.76% |
| 2012 Q3 | 136.27 Billion JPY | 12.34% |
| 2011 Q1 | 125.33 Billion JPY | -17.03% |
| 2011 Q2 | 127.36 Billion JPY | 1.63% |
| 2011 Q3 | 123.09 Billion JPY | -3.35% |
| 2011 Q4 | 143.43 Billion JPY | 16.52% |
| 2011 FY | 519.23 Billion JPY | -3.63% |
| 2010 Q4 | 151.05 Billion JPY | 13.99% |
| 2010 FY | 538.79 Billion JPY | 18.92% |
| 2010 Q1 | 112.41 Billion JPY | 15.91% |
| 2010 Q2 | 142.8 Billion JPY | 27.03% |
| 2010 Q3 | 132.51 Billion JPY | -7.2% |
| 2009 Q1 | 107.37 Billion JPY | 37.81% |
| 2009 Q2 | 114.21 Billion JPY | 6.37% |
| 2009 Q3 | 134.47 Billion JPY | 17.74% |
| 2009 Q4 | 96.98 Billion JPY | -27.88% |
| 2009 FY | 453.05 Billion JPY | 11.03% |
| 2008 FY | 408.02 Billion JPY | -2.23% |
| 2008 Q4 | 77.9 Billion JPY | -25.71% |
| 2008 Q3 | 104.86 Billion JPY | -7.5% |
| 2008 Q2 | 113.37 Billion JPY | 0.0% |
| 2007 FY | 417.34 Billion JPY | -6.44% |
| 2006 FY | 446.04 Billion JPY | 7.91% |
| 2005 FY | 413.34 Billion JPY | 109.83% |
| 2004 FY | 196.99 Billion JPY | -16.69% |
| 2003 FY | 236.45 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 224.77 Billion JPY | -360.14% |
| Chugai Pharmaceutical Co., Ltd. | 258.88 Billion JPY | -299.517% |
| Ono Pharmaceutical Co., Ltd. | 212.44 Billion JPY | -386.859% |
| Santen Pharmaceutical Co., Ltd. | 111.97 Billion JPY | -823.702% |
| JCR Pharmaceuticals Co., Ltd. | 23.72 Billion JPY | -4260.443% |
| Daiichi Sankyo Company, Limited | 974.77 Billion JPY | -6.106% |
| Otsuka Holdings Co., Ltd. | 1115.15 Billion JPY | 7.251% |
| Perseus Proteomics Inc. | 982.41 Million JPY | -105181.175% |